Early Registry Outcomes Suggest TAVR Roll-Out Has Been Successful So Far
This article was originally published in The Gray Sheet
The first report from the U.S. TVT Registry of transcatheter aortic valve replacement shows procedural and in-hospital outcomes comparable to those seen in randomized trials and international registries.
You may also be interested in...
In June 2015, three cardiology societies issued a clinical overview on implantation of left atrial appendage closure devices that is the first in a series of documents highlighting the critical issues that need to be addressed in order to integrate these new technologies into clinical practice.
The American College of Cardiology, Heart Rhythm Society, and Society for Cardiovascular Angiography and Interventions released an overview of left atrial appendage occlusion devices, specifically Boston Scientific's Watchman and SentreHEART's Lariat.
So far, transcatheter aortic valves are only indicated for patients for whom surgery presents high or even intolerable risks. Two-year data from a trial in Scandinavia suggests TAVR could eventually supplant surgical valve replacement in patients at low risk during surgery, but this approach will require more study.